Reducing potentially inappropriate polypharmacy at a national and international level: the impact of deprescribing networks

References

• Masnoon N, Shakib S, Kalisch-Ellett L, et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr. [2017 Oct 10];17(1):230. doi: 10.1186/s12877-017-0621-2
   PubMedGoogle Scholar
• The World Health Organization. Medication Without Harm. [cited 2024 Feb 29. Available from: https://www.who.int/initiatives/medication-without-harm
   Google Scholar
• Mair A, Wilson M, Dreischulte T. Addressing the challenge of polypharmacy. Annu Rev Pharmacol Toxicol. 2020;60(1):661–681. doi: 10.1146/annurev-pharmtox-010919-023508
   PubMed Web of Science ®Google Scholar
• Guillot J, Maumus-Robert S, Marceron A, et al. The burden of potentially inappropriate medications in chronic polypharmacy. J Clin Med. 2020 Nov;9(11):3728. doi: 10.3390/jcm9113728
   PubMed Web of Science ®Google Scholar
• Bhagavathula AS, Gebreyohannes EA, Fialova D. Prevalence of polypharmacy and risks of potentially inappropriate medication use in the older population in a developing country: a systematic review and meta-analysis. Gerontology. [2021 May 11];68(2):136–145. doi: 10.1159/000516075
   PubMed Web of Science ®Google Scholar
• Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med. [1997 Jul 28];157(14):1531–1536. doi: 10.1001/archinte.1997.00440350031003
   PubMedGoogle Scholar
• Motter FR, Fritzen JS, Hilmer SN, et al. Potentially inappropriate medication in the elderly: a systematic review of validated explicit criteria. Eur J Clin Pharmacol. [2018 Jun 1];74(6):679–700. doi: 10.1007/s00228-018-2446-0
   PubMed Web of Science ®Google Scholar
• Government of Canada SC. Prevalence of prescription and non-prescription polypharmacy by frailty and sex among middle-aged and older Canadians. 2022 [cited 2024 Feb 29. Available from: https://www150.statcan.gc.ca/n1/pub/82-003-x/2022006/article/00001-eng.htm
   Google Scholar
• Moriarty F, Hardy C, Bennett K, et al. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. BMJ Open. [2015 Sep 1];5(9):e008656. doi: 10.1136/bmjopen-2015-008656
   PubMed Web of Science ®Google Scholar
• Hovstadius B, Hovstadius K, Astrand B, et al. Increasing polypharmacy – an individual-based study of the Swedish population 2005-2008. BMC Clin Pharmacol. [2010 Dec 2];10(1):16. doi: 10.1186/1472-6904-10-16
   PubMedGoogle Scholar
• Oktora MP, Denig P, Bos JHJ, et al. Trends in polypharmacy and dispensed drugs among adults in the Netherlands as compared to the United States. PLOS ONE. [2019 Mar 22];14(3):e0214240. doi: 10.1371/journal.pone.0214240
   PubMed Web of Science ®Google Scholar
• Maxwell CJ, Mondor L, Koné AJP, et al. Sex differences in multimorbidity and polypharmacy trends: A repeated cross-sectional study of older adults in Ontario, Canada. PLOS ONE. [2021 Apr 26];16(4):e0250567. doi: 10.1371/journal.pone.0250567
   PubMed Web of Science ®Google Scholar
• Kantor ED, Rehm CD, Haas JS, et al. Trends in prescription drug use among adults in the United States from 1999–2012. JAMA. [2015 Nov 3];314(17):1818–1831. doi: 10.1001/jama.2015.13766
   PubMed Web of Science ®Google Scholar
• Shehab N, Lovegrove MC, Geller AI, et al. US emergency department visits for outpatient adverse drug events, 2013-2014. JAMA. [2016 Nov 22];316(20):2115–2125. doi: 10.1001/jama.2016.16201
   PubMed Web of Science ®Google Scholar
• Benmassaoud A, McDonald EG, Lee TC. Potential harms of proton pump inhibitor therapy: rare adverse effects of commonly used drugs. CMAJ. [2016 Jun 14];188(9):657–662. doi: 10.1503/cmaj.150570
   PubMed Web of Science ®Google Scholar
• Heidelbaugh JJ, Kim AH, Chang R, et al. Overutilization of proton-pump inhibitors: what the clinician needs to know. Ther Adv Gastroenterol. 2012 Jul;5(4):219–232. doi: 10.1177/1756283X12437358
   PubMed Web of Science ®Google Scholar
• Morgan SG, Hunt J, Rioux J, et al. Frequency and cost of potentially inappropriate prescribing for older adults: a cross-sectional study. CMAJ Open. [2016 Jun 22];4(2):E346–51. doi: 10.9778/cmajo.20150131
   PubMedGoogle Scholar
• Gnjidic D, Johansson M, Meng DM, et al. Achieving sustainable healthcare through deprescribing. Cochrane Database Syst Rev. [2022 Oct 4];10(10):ED000159. doi: 10.1002/14651858.ED000159
   PubMedGoogle Scholar
• Farrell B, Tsang C, Raman-Wilms L, et al. What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: a modified delphi process. PLOS ONE. 2015;10(4):e0122246. doi: 10.1371/journal.pone.0122246
   PubMed Web of Science ®Google Scholar
• Reeve E, Gnjidic D, Long J, et al. A systematic review of the emerging definition of “deprescribing” with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015 Dec;80(6):1254–1268. doi: 10.1111/bcp.12732
   PubMed Web of Science ®Google Scholar
• Weir KR, Ailabouni NJ, Schneider CR, et al. Consumer attitudes towards deprescribing: a systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci. [2022 May 5];77(5):1020–1034. doi: 10.1093/gerona/glab222
   PubMed Web of Science ®Google Scholar
• Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician Med Fam Can. 2017 May;63(5):354–364.
   PubMed Web of Science ®Google Scholar
• Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline. Can Fam Physician Med Fam Can. 2018 May;64(5):339–351.
   PubMed Web of Science ®Google Scholar
• Farrell B, Black C, Thompson W, et al. Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guideline. Can Fam Physician Med Fam Can. 2017 Nov;63(11):832–843.
   PubMed Web of Science ®Google Scholar
• Reeve E, Thompson W, Boyd C, et al. The state of deprescribing research: How did we get here? Basic Clin Pharmacol Toxicol. 2023 Dec;133(6):657–660. doi: 10.1111/bcpt.13862
   PubMed Web of Science ®Google Scholar
• Admin. How to build an academic network. International Research Network for the Study of Science & Belief in Society. 2021 [cited 2024 Feb 29. Available from: https://scienceandbeliefinsociety.org/2021/02/15/how-to-build-an-academic-network/
   Google Scholar
• Onder G, Vetrano DL, Palmer K, et al. Italian guidelines on management of persons with multimorbidity and polypharmacy. Aging Clin Exp Res. 2022 May;34(5):989–996. doi: 10.1007/s40520-022-02094-z
   PubMed Web of Science ®Google Scholar
• Stewart D, Mair A, Wilson M, et al. Guidance to manage inappropriate polypharmacy in older people: systematic review and future developments. Expert Opin Drug Saf. 2017 Feb;16(2):203–213. doi: 10.1080/14740338.2017.1265503
   PubMed Web of Science ®Google Scholar
• Quality Use of Medicines to Optimise Ageing in Older Australians: Recommendationsfor a National Strategic Action Plan to Reduce Inappropriate Polypharmacy. NHMRCCognitive Decline Partnership Centre, University of Sydney, in Collaboration with the AustralianDeprescribing Network and NPS MedicineWise. Sydney, NSW, Australia. 2018.
   Google Scholar
• Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. [2015 May 1];175(5):827. doi: 10.1001/jamainternmed.2015.0324
   PubMed Web of Science ®Google Scholar
• Reeve E, To J, Hendrix I, et al. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. [2013 Oct 1];30(10):793–807. doi: 10.1007/s40266-013-0106-8
   PubMed Web of Science ®Google Scholar
• Kouladjian O’Donnell L, Reeve E, Cumming A, et al. Development and dissemination of the national strategic action plan for reducing inappropriate polypharmacy in older Australians. Int Med J. 2021 Jan;51(1):111–115. doi: 10.1111/imj.15155
   Google Scholar
• Etherton-Beer C, Page A, Naganathan V, et al. Deprescribing to optimise health outcomes for frail older people: a double-blind placebo-controlled randomised controlled trial-outcomes of the Opti-med study. Age Ageing. [2023 May 1];52(5):afad081. doi: 10.1093/ageing/afad081
   PubMed Web of Science ®Google Scholar
• Reeve E, Low LF, Shakib S, et al. Development and validation of the revised patients’ attitudes towards deprescribing (rPATD) questionnaire: versions for older adults and caregivers. Drugs Aging. [2016 Dec 1];33(12):913–928. doi: 10.1007/s40266-016-0410-1
   PubMed Web of Science ®Google Scholar
• Deprescribing tools – NSW Therapeutic Advisory Group. NSW therapeutic advisory group – the new south wales therapeutic advisory group Inc. (NSW TAG) is an independent, not-for-profit member-based organisation, comprised of clinical pharmacologists, pharmacists, nurses and clinicians committed to promoting quality use of medicines (QUM) in NSW public hospitals and the wider community. 2021 [cited 2024 May 2. Available from: https://www.nswtag.org.au/deprescribing-tools/
   Google Scholar
• Polypharmacy QUM Indicators and Resources – NSW Therapeutic Advisory Group. NSW therapeutic advisory group – the new south wales therapeutic advisory group Inc. (NSW TAG) is an independent, not-for-profit member-based organisation, comprised of clinical pharmacologists, pharmacists, nurses and clinicians committed to promoting quality use of medicines (QUM) in NSW public hospitals and the wider community. 2022 [cited 2024 May 2. Available from: https://www.nswtag.org.au/polypharmacy-qum-indicators-and-resources/
   Google Scholar
• Langford AV, Lin CC, Bero L, et al. Clinical practice guideline for deprescribing opioid analgesics: summary of recommendations. Med J Aust. [2023 Jul 17];219(2):80–89. doi: 10.5694/mja2.52002
   PubMed Web of Science ®Google Scholar
• Reeve E, Farrell B, Thompson W, et al. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. Med J Aust. 2019 Mar;210(4):174–179. doi: 10.5694/mja2.50015
   PubMed Web of Science ®Google Scholar
• Charbonneau M, Morgan SG, Gagnon C, et al. Factors influencing the effects of policies and interventions to promote the appropriate use of medicines in high-income countries: A rapid realist review. Health Policy. [2024 Feb 24];142:105027. doi: 10.1016/j.healthpol.2024.105027
   PubMed Web of Science ®Google Scholar
• McDonald EG, Wu PE, Rashidi B, et al. The MedSafer study – electronic decision support for deprescribing in hospitalized older adults: a cluster randomized clinical trial. JAMA Intern Med. [2022 Mar 1];182(3):265. doi: 10.1001/jamainternmed.2021.7429
   PubMed Web of Science ®Google Scholar
• Tannenbaum C, Martin P, Tamblyn R, et al. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014 Jun;174(6):890–898. doi: 10.1001/jamainternmed.2014.949
   PubMed Web of Science ®Google Scholar
• Farrell B, Raman-Wilms L, Sadowski CA, et al. A proposed curricular framework for an interprofessional approach to deprescribing. Med Sci Educ. [2023 Apr 1];33(2):551–567. doi: 10.1007/s40670-022-01704-9
   PubMedGoogle Scholar
• Canadian Medication Appropriatness and Deprescribing Network. Do I still need this medication? Is deprescribing for you? [Internet]. [Translated resources. Available from cited 2024 Feb 29]. Available from https://www.deprescribingnetwork.ca/translated-resources.
   Google Scholar
• Steinman MA, Landefeld CS. Overcoming inertia to improve medication use and deprescribing: patients, pharmacists, and physicians. JAMA. [2018 Nov 13];320(18):1867–1869. doi: 10.1001/jama.2018.16473
   PubMed Web of Science ®Google Scholar
• Anderson K, Stowasser D, Freeman C, et al. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. [2014 Dec 1];4(12):e006544. doi: 10.1136/bmjopen-2014-006544
   PubMed Web of Science ®Google Scholar
• Bayliss EA, Albers K, Gleason K, et al. Recommendations for outcome measurement for deprescribing intervention studies. J Am Geriatr Soc. 2022 Sep;70(9):2487–2497. doi: 10.1111/jgs.17894
   PubMed Web of Science ®Google Scholar
• Lundby C, Graabaek T, Ryg J, et al. Health care professionals’ attitudes towards deprescribing in older patients with limited life expectancy: A systematic review. Br J Clin Pharmacol. 2019 May;85(5):868–892. doi: 10.1111/bcp.13861
   PubMed Web of Science ®Google Scholar
• Scott S, Wright DJ, Bhattacharya D. The role of behavioural science in changing deprescribing practice. Br J Clin Pharmacol. 2021;87(1):39–41. doi: 10.1111/bcp.14595
   PubMed Web of Science ®Google Scholar
• Lundby C, Thompson W. Advancing deprescribing: Learnings from the first international conference on deprescribing. Basic Clin Pharmacol Toxicol. 2024;134(1):3–5. doi: 10.1111/bcpt.13963
   PubMed Web of Science ®Google Scholar
• Thompson W, Lundby C, Bleik A, et al. Measuring quality of life in deprescribing trials: a scoping review. Drugs Aging. [2024 Mar 20]. doi: 10.1007/s40266-024-01113-0
   Web of Science ®Google Scholar
• Scott IA. Deprescribing: a 20-year retrospective. J Pharm Pract Res. 2023;53(6):320–327. doi: 10.1002/jppr.1906
   Web of Science ®Google Scholar
• Past annual meetings | australian deprescribing network. [cited 2024 Feb 29. Available from: https://www.australiandeprescribingnetwork.com.au/__trashed-5/
   Google Scholar
• Software B. MedsAware: Deprescribing action week. [cited 2024 Feb 29. Available from: https://shpa.org.au/news-advocacy/MedsAware?v=638447984246485995
   Google Scholar
• Reeve E, Johnson JL, Sluggett J, O’Hara K The Conversation. Taking more than 5 pills a day? ‘Deprescribing’ can prevent harm – especially for older people. Available from 2023 [cited 2024 Feb 29]. Available from: http://theconversation.com/taking-more-than-5-pills-a-day-deprescribing-can-prevent-harm-especially-for-older-people-211424
   Google Scholar
• Canadian Medication Appropriateness and Deprescribing Network. Canadian deprescribing network annual report 2016. [cited 2024 Feb 29. Available from: https://static1.squarespace.com/static/5836f01fe6f2e1fa62c11f08/t/58ed2f32e58c6291cf3084dc/1491939137438/CaDeN_Annual+Report_23Jan2017_EN_WEB.pdf
   Google Scholar
• Tannenbaum C, Farrell B, Shaw J, et al. An ecological approach to reducing potentially inappropriate medication use: canadian deprescribing network. Can J Aging Rev Can Vieil. 2017 Mar;36(1):97–107. doi: 10.1017/S0714980816000702
   PubMed Web of Science ®Google Scholar
• Turner JP, Currie J, Trimble J, et al. Strategies to promote public engagement around deprescribing. Ther Adv Drug Saf. [2018 Sep 12];9(11):653–665. doi: 10.1177/2042098618794165
   PubMed Web of Science ®Google Scholar
• Canadian Medication Appropriateness and Deprescribing Network. Do I still need this medication? Is deprescribing for you? Resources. Available from cited 2024 Feb 29]. Available from https://www.deprescribingnetwork.ca/useful-resources
   Google Scholar
• Martin P, Tamblyn R, Benedetti A, et al. Effect of a pharmacist-led educational intervention on inappropriate medication prescriptions in older adults: the d-prescribe randomized clinical trial. JAMA. [2018 Nov 13];320(18):1889–1898. doi: 10.1001/jama.2018.16131
   PubMed Web of Science ®Google Scholar
• Turner JP, Gagnon CL, Khuong NB, et al. The impact of educational whiteboard videos on healthcare providers’ self-efficacy to deprescribe. J Am Geriatr Soc. 2023 May;71(5):E15–8. doi: 10.1111/jgs.18335
   PubMed Web of Science ®Google Scholar
• Canadian Medication Appropriateness and Deprescribing Network. Do I still need this medication? Is deprescribing for you?. [Deprescribing Policy. Available from cited 2024 Feb 29]. Available from https://www.deprescribingnetwork.ca/policy
   Google Scholar
• Canadian Medication Appropriateness and Deprescribing Network. Government of Canada names head of the Canadian drug agency transition office. 2021 [cited 2022 Sep 12. Available from: https://www.canada.ca/en/health-canada/news/2021/04/government-of-canada-names-head-of-the-canadian-drug-agency-transition-office.html
   Google Scholar
• Do I still need this medication? Is deprescribing for you? Research affiliates. Available from cited 2024 Feb 29]. Available from: https://www.deprescribingnetwork.ca/research-affiliates
   Google Scholar
• SaferMedsNL. [cited 2024 Feb 29. Available from: https://safermedsnl.ca/
   Google Scholar
• Turner JP, Caetano P, Tannenbaum C. Leveraging policy to reduce chronic opioid use by educating and empowering community dwelling adults: a study protocol for the TAPERING randomized controlled trial. Trials. [2019 Jul 9];20(1):412. doi: 10.1186/s13063-019-3508-z
   PubMedGoogle Scholar
• Murphy AL, Turner JP, Rajda M, et al. A protocol for a randomized controlled trial comparing sleepwell, EMPOWER, and treatment-as-usual for benzodiazepine receptor agonist discontinuation in older adults: the your answers when needing sleep in New Brunswick (YAWNS NB) study. Explor Res Clin Soc Pharm. [2022 Aug 3];7:100164. doi: 10.1016/j.rcsop.2022.100164
   PubMedGoogle Scholar
• US deprescribing research network. [cited 2024 Feb 29. Home. Available from: https://deprescribingresearch.org/
   Google Scholar
• Merton L, Nicole B, Carmen ER, et al. Practical incorporation of stakeholder-informed ethics into research funding decisions | progress in community health partnerships: research, education, and action. [cited 2024 Feb 29. Available from: https://preprint.press.jhu.edu/pchp/preprints/practical-incorporation-stakeholder-informed-ethics-research-funding-decisions
   Google Scholar
• Dublin S, Albertson-Junkans L, Nguyen TPP, Pavon JM, Hastings SN, Maciejewski ML, et al. Defining key deprescribing measures from electronic health data: a multisite data harmonization project. medRxiv; 2023 [cited 2024 Feb 29]. 2023.11.06.23298060. Available from: https://www.medrxiv.org/content/10.1101/2023.11.06.23298060v1
   Google Scholar
• The Canadian Institute for Health Information. Newfoundland and labrador - potentially inappropriate medication prescribed to seniors. [cited 2024 Feb 29. Available from: https://yourhealthsystem.cihi.ca/hsp/indepth?lang=en#/indicator/047/2/C10151/
   Google Scholar